| pubmed-article:8847965 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C1882598 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C0018546 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C0059563 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C0332285 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C0520739 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C0870883 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:8847965 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8847965 | pubmed:issue | 26 | lld:pubmed |
| pubmed-article:8847965 | pubmed:dateCreated | 1996-10-21 | lld:pubmed |
| pubmed-article:8847965 | pubmed:abstractText | The levels of haloperidol (HP) and its pyridinium metabolite HPP+ were estimated in plasma and brain tissues of rats treated i.p. with HP (10 mg/kg). HP and HPP+ levels in plasma decreased linearly during the 0-3 hour period following drug administration. On the other hand, HPP+ levels in brain tissues increased gradually during the same period. HPP+ levels in brain tissues increased further when HP (10 mg/kg) was injected for three consecutive days. The formation of HPP+ also was studied in rat brain mitochondrial and liver microsomal preparations. Enzyme activity responsible for the conversion of HP to HPP+ was not found in brain mitochondria. Liver microsomal enzymes catalyzed the oxidation of HP and its tetrahydropyridine dehydration product HPTP to HPP+ with about the same efficiency. Studies employing several cytochrome P450 inhibitors and anti-cytochrome P450 antibodies were carried out in an effort to identify the forms of cytochrome P450 that are responsible for catalyzing the oxidation of HP and HPTP to HPP+. The formation of HPP+ in liver microsomes was strongly inhibited by ketoconazole and nifedipine and by an anti-CYP3A antibody. These results suggest that formation of HPP+ from HP and HPTP in rat liver microsomes is catalyzed mainly by CYP3A although the participation of other P450 forms cannot be ruled out. | lld:pubmed |
| pubmed-article:8847965 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8847965 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847965 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8847965 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:8847965 | pubmed:issn | 0024-3205 | lld:pubmed |
| pubmed-article:8847965 | pubmed:author | pubmed-author:IgarashiKK | lld:pubmed |
| pubmed-article:8847965 | pubmed:author | pubmed-author:FukuiMM | lld:pubmed |
| pubmed-article:8847965 | pubmed:author | pubmed-author:CastagnoliNNJ... | lld:pubmed |
| pubmed-article:8847965 | pubmed:author | pubmed-author:KasuyaFF | lld:pubmed |
| pubmed-article:8847965 | pubmed:author | pubmed-author:UsukiEE | lld:pubmed |
| pubmed-article:8847965 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8847965 | pubmed:day | 17 | lld:pubmed |
| pubmed-article:8847965 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:8847965 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8847965 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8847965 | pubmed:pagination | 2439-46 | lld:pubmed |
| pubmed-article:8847965 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:meshHeading | pubmed-meshheading:8847965-... | lld:pubmed |
| pubmed-article:8847965 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8847965 | pubmed:articleTitle | Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP. | lld:pubmed |
| pubmed-article:8847965 | pubmed:affiliation | Faculty of Pharmaceutical Sciences, Kobegakuin University, Kobe, Japan. | lld:pubmed |
| pubmed-article:8847965 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8847965 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8847965 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8847965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8847965 | lld:pubmed |
